HOME    |    SITEMAP    |    CONTACT    |    

Share  | 

News   ( View All )


  • 03/02/15 - Mersana Raises $35 Million in Series B Financing and Appoints Anna Protopapas as President and Chief Executive Officer Read More
  • 01/12/15 - Mersana Therapeutics and Takeda Expand Antibody-Drug Conjugate Partnership Read More
  • 10/27/14 - Mersana and Takeda Enter Commercial License Agreement for Novel Fleximer® Antibody-Drug Conjugate Read More

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes.


Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address multiple unmet needs in oncology. Our versatile conjugation system integrates Fleximer®, a clinically validated biodegradable polymer, with a broad array of customizable linker chemistries matched to therapeutic payloads. Our technology is being leveraged in multiple therapeutic areas through partnerships.